Mental Process
Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years
Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare
FDA Delays Decision on Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Until April 2025
Barth Syndrome, Elamipretide, FDA Decision, Stealth BioTherapeutics, Drug Approval Delay
Biotech IPO Market Expected to Rebound in 2025 with Increased Investor Optimism
Biotech IPOs, 2025 Outlook, Investor Optimism, Therapeutic Innovation, Strategic Differentiation
Accelerating Alzheimer’s Research: The Alzheimer’s Drug Discovery Foundation
Alzheimer’s disease, drug discovery, research funding, venture philanthropy, cognitive aging, dementia treatments
Narsoplimab Demonstrates Significant Survival Benefit in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Narsoplimab, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), Lectin Pathway Inhibition, MASP-2 Inhibitor, Rare Disease Treatment, Overall Survival Improvement
Outlook Therapeutics Announces Strategic Workforce Reduction to Streamline Operations
Outlook Therapeutics, workforce reduction, biopharmaceutical company, strategic restructuring, cost-saving measures, LYTENAVA, bevacizumab gamma, wet AMD treatment.
Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment
Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning
Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens
Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder
Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance
Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch
Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development